A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

Inclusion Criteria:

• Female or male adults with Type 1 diabetes
• Ages 18-65 years
• Type 1 DM for at least 3 years
• Using an insulin pump or multiple daily injections (MDI) for at least 3 months
• BMI 25.0 - 35.0

Exclusion Criteria:

• Significant medical history
• Uncontrolled diabetes
• History of surgical treatment for weight loss
• History of malignancy